Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted investor meetings with the company’s CFO following Boston Scientific’s Q4 earnings report. The firm left these meetings “encouraged” that the initial 2025 Boston Scientific guidance is “prudently conservative” and Brennan’s comments suggested that that Boston Scientific is well-positioned for significant operating leverage opportunities as 2025 unfolds, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $118 from $111 at Barclays
- Boston Scientific price target raised to $122 from $119 at Raymond James
- Boston Scientific price target raised to $120 from $110 at Truist
- Boston Scientific price target raised to $115 from $100 at Stifel
- Boston Scientific price target raised to $120 from $112 at Baird
Questions or Comments about the article? Write to editor@tipranks.com